Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who were aged between 18 and 65 years old when their symptoms first began, of any gender.
• People who have been diagnosed with Alzheimer's-related mild cognitive impairment or mild Alzheimer's disease, based on recognised diagnostic guidelines (NIA-AA 2011).
• People whose diagnosis has been confirmed by a brain scan (PET/CT or PET/MRI) or a spinal fluid test showing the presence of amyloid-beta protein.
• People who score at or above certain thresholds on standard memory and thinking tests (MMSE score of 21 or higher, MoCA score of 17 or higher, or a CDR score of 0.5).
• People whose neurological examination shows no significant abnormal findings.
• People who are able to complete cognitive assessments and other study-related tests.
• People (and their legal guardians) who have given written, dated consent to participate and have agreed to follow all study procedures.

Who may not be able to join:

• People whose memory or thinking problems are caused by something other than Alzheimer's disease, such as stroke-related brain changes, brain infections, Huntington's disease, Parkinson's disease, Lewy body dementia, head injury, alcohol or drug use, significant organ disease, brain tumours, thyroid or parathyroid disorders, or vitamin deficiencies.
• People who have had a stroke, a transient ischemic attack (a brief, stroke-like episode), a bleeding disorder, or seizures within the past 12 months, or who have other unstable medical conditions.
• People who have been diagnosed with schizophrenia, bipolar disorder, major depression, delirium, or other serious psychiatric conditions as defined by DSM-IV criteria.
• People with unstable or severe heart, lung, liver, kidney, or blood disorders, or those with a known cancer diagnosis or another condition with a serious outlook.
• People who have a specific inflammatory condition related to amyloid protein in the brain's blood vessels (known as CAAri/ABRA) (confirm with trial site).
• People with vision or hearing problems that cannot be corrected and that would prevent them from completing the study assessments.
• People who are unable to have an MRI scan, for example due to claustrophobia, or because they have a pacemaker, defibrillator, or certain metal implants in their body.
• People whose MRI scan shows more than four small brain bleeds, signs of iron deposits on the brain surface, fluid build-up around blood vessels, extensive white matter changes, multiple small strokes, a major stroke, brain bruising, areas of softened brain tissue, brain aneurysms, other blood vessel abnormalities, brain infections, or brain tumours other than certain benign types (meningiomas or arachnoid cysts).
• People who are taking blood-thinning medications such as warfarin, vitamin K antagonists, or direct oral anticoagulants (including dabigatran, rivaroxaban, edoxaban, apixaban, or betrixaban), heparin, or clot-dissolving treatments, or who have a clotting disorder.
• People who are pregnant or breastfeeding.
• People who have a known severe allergy to lecanemab or any of its ingredients.
• People considered unsuitable for the trial by the treating clinician for any other reason.

Important: Always verify eligibility with the trial site directly before applying.